home / stock / morf / morf news

MORF News and Press, Morphic Holding Inc. From 05/27/20

Stock Information
Company Name: Morphic Holding Inc.
Stock Symbol: MORF
Market: NASDAQ
Website: morphictx.com
Menu
MORF MORF Quote MORF Short MORF News MORF Articles MORF Message Board
Get MORF Alerts

News, Short Squeeze, Breakout and More Instantly...
MORF - Morphic to Present at the Jefferies Virtual Healthcare Conference

WALTHAM, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is sched...
MORF - Morphic (MORF) Presents At Bank of America Healthcare Virtual Conference 2020 - Slideshow

The following slide deck was published by Morphic Holding, Inc. in conjunction with this Read more ...

MORF - Morphic EPS misses by $0.07, beats on revenue

Morphic (NASDAQ: MORF ): Q1 GAAP EPS of -$0.55 misses by $0.07 . Revenue of $5.6M (-8.2% Y/Y) beats by $1.13M . Press Release More news on: Morphic Holding, Inc., Earnings news and commentary, Healthcare stocks news,

MORF - Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results

Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as CFO and COO WALTHAM, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharm...
MORF - Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference

WALTHAM, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is sch...

MORF - Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer

WALTHAM, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Marc Schegerin, M.D., as chief financia...

MORF - Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer

WALTHAM, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Peter G. Linde, M.D., as chief medical ...
MORF - Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference

WALTHAM, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president...

MORF - Morphic EPS beats by $0.31, misses on revenue

Morphic (NASDAQ: MORF ): FY GAAP EPS of -$2.69 beats by $0.31 . More news on: Morphic Holding, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

MORF - Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019

WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the fu...
Previous 10 Next 10